Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 52

1.

Major clinical response to nivolumab in relapsed/refractory Hodgkin lymphoma after allogeneic stem cell transplantation.

Yared JA, Hardy N, Singh Z, Hajj S, Badros AZ, Kocoglu M, Yanovich S, Sausville EA, Ujjani C, Ruehle K, Goecke C, Landau M, Rapoport AP.

Bone Marrow Transplant. 2016 Jun;51(6):850-2. doi: 10.1038/bmt.2015.346. Epub 2016 Feb 1. No abstract available.

PMID:
26828905
2.

NY-ESO-1-specific TCR-engineered T cells mediate sustained antigen-specific antitumor effects in myeloma.

Rapoport AP, Stadtmauer EA, Binder-Scholl GK, Goloubeva O, Vogl DT, Lacey SF, Badros AZ, Garfall A, Weiss B, Finklestein J, Kulikovskaya I, Sinha SK, Kronsberg S, Gupta M, Bond S, Melchiori L, Brewer JE, Bennett AD, Gerry AB, Pumphrey NJ, Williams D, Tayton-Martin HK, Ribeiro L, Holdich T, Yanovich S, Hardy N, Yared J, Kerr N, Philip S, Westphal S, Siegel DL, Levine BL, Jakobsen BK, Kalos M, June CH.

Nat Med. 2015 Aug;21(8):914-21. doi: 10.1038/nm.3910. Epub 2015 Jul 20.

3.

Disparities in black and white patients with multiple myeloma referred for autologous hematopoietic transplantation: a single center study.

Bhatnagar V, Wu Y, Goloubeva OG, Ruehle KT, Milliron TE, Harris CG, Rapoport AP, Yanovich S, Sausville EA, Baer MR, Badros AZ.

Cancer. 2015 Apr 1;121(7):1064-70. doi: 10.1002/cncr.29160. Epub 2014 Dec 2.

4.

Combination immunotherapy after ASCT for multiple myeloma using MAGE-A3/Poly-ICLC immunizations followed by adoptive transfer of vaccine-primed and costimulated autologous T cells.

Rapoport AP, Aqui NA, Stadtmauer EA, Vogl DT, Xu YY, Kalos M, Cai L, Fang HB, Weiss BM, Badros A, Yanovich S, Akpek G, Tsao P, Cross A, Mann D, Philip S, Kerr N, Brennan A, Zheng Z, Ruehle K, Milliron T, Strome SE, Salazar AM, Levine BL, June CH.

Clin Cancer Res. 2014 Mar 1;20(5):1355-65. doi: 10.1158/1078-0432.CCR-13-2817. Epub 2014 Feb 11.

5.

Splenectomy as a measure to treat prolonged post-transplant cytopenia associated with hypersplenism.

Brauer DL, Rapoport AP, Yanovich S, Akpek G.

Bone Marrow Transplant. 2014 May;49(5):717-9. doi: 10.1038/bmt.2013.238. Epub 2014 Jan 20. No abstract available.

PMID:
24442253
6.

Single center experience with total body irradiation and melphalan (TBI-MEL) myeloablative conditioning regimen for allogeneic stem cell transplantation (SCT) in patients with refractory hematologic malignancies.

Bhatnagar B, Rapoport AP, Fang HB, Ilyas C, Marangoz D, Akbulut V, Ruehle K, Badros A, Yanovich S, Akpek G.

Ann Hematol. 2014 Apr;93(4):653-60. doi: 10.1007/s00277-013-1908-9. Epub 2013 Oct 6.

PMID:
24097082
7.

Peripheral-blood stem cells versus bone marrow from unrelated donors.

Anasetti C, Logan BR, Lee SJ, Waller EK, Weisdorf DJ, Wingard JR, Cutler CS, Westervelt P, Woolfrey A, Couban S, Ehninger G, Johnston L, Maziarz RT, Pulsipher MA, Porter DL, Mineishi S, McCarty JM, Khan SP, Anderlini P, Bensinger WI, Leitman SF, Rowley SD, Bredeson C, Carter SL, Horowitz MM, Confer DL; Blood and Marrow Transplant Clinical Trials Network..

N Engl J Med. 2012 Oct 18;367(16):1487-96. doi: 10.1056/NEJMoa1203517.

8.

Cellular therapy with sequential unmanipulated donor lymphocyte infusions in drug-resistant cytomegalovirus (CMV) encephalitis.

Akpek G, Mikulski M, Kleinberg M, Badros A, Yanovich S, Rapoport AP.

Blood. 2011 May 26;117(21):5772-4. doi: 10.1182/blood-2011-02-334060. No abstract available.

9.

Combination immunotherapy using adoptive T-cell transfer and tumor antigen vaccination on the basis of hTERT and survivin after ASCT for myeloma.

Rapoport AP, Aqui NA, Stadtmauer EA, Vogl DT, Fang HB, Cai L, Janofsky S, Chew A, Storek J, Akpek G, Badros A, Yanovich S, Tan MT, Veloso E, Pasetti MF, Cross A, Philip S, Murphy H, Bhagat R, Zheng Z, Milliron T, Cotte J, Cannon A, Levine BL, Vonderheide RH, June CH.

Blood. 2011 Jan 20;117(3):788-97. doi: 10.1182/blood-2010-08-299396. Epub 2010 Oct 28.

10.

Rapid immune recovery and graft-versus-host disease-like engraftment syndrome following adoptive transfer of Costimulated autologous T cells.

Rapoport AP, Stadtmauer EA, Aqui N, Vogl D, Chew A, Fang HB, Janofsky S, Yager K, Veloso E, Zheng Z, Milliron T, Westphal S, Cotte J, Huynh H, Cannon A, Yanovich S, Akpek G, Tan M, Virts K, Ruehle K, Harris C, Philip S, Vonderheide RH, Levine BL, June CH.

Clin Cancer Res. 2009 Jul 1;15(13):4499-507. doi: 10.1158/1078-0432.CCR-09-0418. Epub 2009 Jun 9.

11.
12.

A scheme for defining cause of death and its application in the T cell depletion trial.

Copelan E, Casper JT, Carter SL, van Burik JA, Hurd D, Mendizabal AM, Wagner JE, Yanovich S, Kernan NA.

Biol Blood Marrow Transplant. 2007 Dec;13(12):1469-76.

13.

The effect of unrelated donor marrow transplantation on health-related quality of life: a report of the unrelated donor marrow transplantation trial (T-cell depletion trial).

Altmaier EM, Ewell M, McQuellon R, Geller N, Carter SL, Henslee-Downey J, Davies S, Papadopoulos E, Yanovich S, Gingrich R.

Biol Blood Marrow Transplant. 2006 Jun;12(6):648-55.

14.

Influence of T-cell depletion on chronic graft-versus-host disease: results of a multicenter randomized trial in unrelated marrow donor transplantation.

Pavletic SZ, Carter SL, Kernan NA, Henslee-Downey J, Mendizabal AM, Papadopoulos E, Gingrich R, Casper J, Yanovich S, Weisdorf D; National Heart, Lung, and Blood Institute Unrelated Donor Marrow Transplantation Trial..

Blood. 2005 Nov 1;106(9):3308-13. Epub 2005 Jul 26.

15.

Economic analysis of unrelated allogeneic bone marrow transplantation: results from the randomized clinical trial of T-cell depletion vs unmanipulated grafts for the prevention of graft-versus-host disease.

de Lissovoy G, Hurd D, Carter S, Beatty P, Ewell M, Henslee-Downey J, Kernan N, Yanovich S, Weisdorf D.

Bone Marrow Transplant. 2005 Sep;36(6):539-46.

PMID:
16044144
16.

CMV-induced hemorrhagic cystitis as a complication of peripheral blood stem cell transplantation: case report.

Tutuncuoglu SO, Yanovich S, Ozdemirli M.

Bone Marrow Transplant. 2005 Aug;36(3):265-6. No abstract available.

PMID:
15937503
17.

Palifermin for oral mucositis after intensive therapy for hematologic cancers.

Spielberger R, Stiff P, Bensinger W, Gentile T, Weisdorf D, Kewalramani T, Shea T, Yanovich S, Hansen K, Noga S, McCarty J, LeMaistre CF, Sung EC, Blazar BR, Elhardt D, Chen MG, Emmanouilides C.

N Engl J Med. 2004 Dec 16;351(25):2590-8.

18.

Breast tumor contamination of PBSC harvests: tumor depletion by positive selection of CD34(+) cells.

Burgess J, Mills B, Griffith M, Mansour V, Weaver CH, Schwartzberg LS, Snyder EL, Krause DS, Yanovich S, Prilutskaya M, Umiel T, Moss TJ.

Cytotherapy. 2001;3(4):285-94.

PMID:
12171717
19.

Safety and pharmacokinetics of oral voriconazole in patients at risk of fungal infection: a dose escalation study.

Lazarus HM, Blumer JL, Yanovich S, Schlamm H, Romero A.

J Clin Pharmacol. 2002 Apr;42(4):395-402.

PMID:
11936564
20.

Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever.

Walsh TJ, Pappas P, Winston DJ, Lazarus HM, Petersen F, Raffalli J, Yanovich S, Stiff P, Greenberg R, Donowitz G, Schuster M, Reboli A, Wingard J, Arndt C, Reinhardt J, Hadley S, Finberg R, Laverdière M, Perfect J, Garber G, Fioritoni G, Anaissie E, Lee J; National Institute of Allergy and Infectious Diseases Mycoses Study Group..

N Engl J Med. 2002 Jan 24;346(4):225-34. Erratum in: N Engl J Med. 2007 Feb 15;356(7):760.

Supplemental Content

Loading ...
Support Center